Protagenic Therapeutics Stock Performance
| PTIX Stock | USD 1.28 0.10 7.25% |
On a scale of 0 to 100, Protagenic Therapeutics holds a performance score of 9. The company holds a Beta of 1.64, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Protagenic Therapeutics will likely underperform. Please check Protagenic Therapeutics' potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Protagenic Therapeutics' historical price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Protagenic Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak forward indicators, Protagenic Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:4 | Dividend Date 2016-07-27 | Last Split Date 2023-03-23 |
1 | Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders | 02/13/2024 |
2 | Acquisition by Khalil Barrage of 180000 shares of Protagenic Therapeutics at 3.65 subject to Rule 16b-3 | 03/07/2024 |
3 | Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice | 03/21/2024 |
4 | Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders | 03/27/2024 |
5 | Protagenic Therapeutics, Inc. Q4 2023 Earnings Call Transcript | 04/02/2024 |
6 | Acquisition by Alexander Arrow of 8000 shares of Protagenic Therapeutics at 0.81 subject to Rule 16b-3 | 04/08/2024 |
7 | Protagenic Therapeutics Innovative Peptide PT00114 to be Highlighted at Boston Summit | 04/17/2024 |
8 | Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial | 05/01/2024 |
| Begin Period Cash Flow | 215.2 K | |
| Free Cash Flow | -3.9 M |
Protagenic |
Protagenic Therapeutics Relative Risk vs. Return Landscape
If you would invest 84.00 in Protagenic Therapeutics on February 5, 2024 and sell it today you would earn a total of 44.00 from holding Protagenic Therapeutics or generate 52.38% return on investment over 90 days. Protagenic Therapeutics is currently generating 0.8984% in daily expected returns and assumes 7.0625% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than Protagenic, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Protagenic Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protagenic Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Protagenic Therapeutics, and traders can use it to determine the average amount a Protagenic Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1272
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PTIX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.06 actual daily | 62 62% of assets are less volatile |
Expected Return
| 0.9 actual daily | 17 83% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Protagenic Therapeutics is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Protagenic Therapeutics by adding it to a well-diversified portfolio.
Protagenic Therapeutics Fundamentals Growth
Protagenic Stock prices reflect investors' perceptions of the future prospects and financial health of Protagenic Therapeutics, and Protagenic Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protagenic Stock performance.
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 1.62 M | ||||
| Shares Outstanding | 4.44 M | ||||
| Price To Earning | 9.43 X | ||||
| Price To Book | 1.74 X | ||||
| EBITDA | (4.5 M) | ||||
| Net Income | (5 M) | ||||
| Cash And Equivalents | 8.87 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 344.23 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 19.47 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (3.7 M) | ||||
| Earnings Per Share | (1.15) X | ||||
| Market Capitalization | 5.68 M | ||||
| Total Asset | 4.32 M | ||||
| Retained Earnings | (30.78 M) | ||||
| Working Capital | 3.54 M | ||||
| Current Asset | 3.75 M | ||||
| Current Liabilities | 736 K | ||||
About Protagenic Therapeutics Performance
To evaluate Protagenic Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Protagenic Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Protagenic Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Protagenic Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Protagenic's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 269.53 | 275.10 | |
| Return On Tangible Assets | (1.16) | (1.21) | |
| Return On Capital Employed | (1.23) | (1.17) | |
| Return On Assets | (1.16) | (1.21) | |
| Return On Equity | (1.36) | (1.30) |
Things to note about Protagenic Therapeutics performance evaluation
Checking the ongoing alerts about Protagenic Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protagenic Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protagenic Therapeutics is way too risky over 90 days horizon | |
| Protagenic Therapeutics may become a speculative penny stock | |
| Protagenic Therapeutics appears to be risky and price may revert if volatility continues | |
| Protagenic Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protagenic Therapeutics currently holds about 8.87 M in cash with (3.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from accesswire.com: Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial |
- Analyzing Protagenic Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protagenic Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protagenic Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protagenic Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protagenic Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protagenic Therapeutics' stock. These opinions can provide insight into Protagenic Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagenic Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Protagenic Stock analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Protagenic Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. If investors know Protagenic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagenic Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.15) | Return On Assets (0.46) | Return On Equity (0.94) |
The market value of Protagenic Therapeutics is measured differently than its book value, which is the value of Protagenic that is recorded on the company's balance sheet. Investors also form their own opinion of Protagenic Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagenic Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagenic Therapeutics' market value can be influenced by many factors that don't directly affect Protagenic Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagenic Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagenic Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.